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Abstract
Recent clinical evidence suggests important role of lipid and amino acid metabolism in early pre-autoimmune stages of type
1 diabetes pathogenesis. We study the molecular paths associated with the incidence of insulitis and type 1 diabetes in the
Non-Obese Diabetic (NOD) mouse model using available gene expression data from the pancreatic tissue from young pre-
diabetic mice. We apply a graph-theoretic approach by using a modified color coding algorithm to detect optimal
molecular paths associated with specific phenotypes in an integrated biological network encompassing heterogeneous
interaction data types. In agreement with our recent clinical findings, we identified a path downregulated in early insulitis
involving dihydroxyacetone phosphate acyltransferase (DHAPAT), a key regulator of ether phospholipid synthesis. The
pathway involving serine/threonine-protein phosphatase (PP2A), an upstream regulator of lipid metabolism and insulin
secretion, was found upregulated in early insulitis. Our findings provide further evidence for an important role of lipid
metabolism in early stages of type 1 diabetes pathogenesis, as well as suggest that such dysregulation of lipids and related
increased oxidative stress can be tracked to beta cells.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease that results in
destruction of insulin-producing beta cells of the pancreas [1]. The
early stages of T1D pathogenesis are characterized by insulitis, an
inflammation of the islets of Langerhans of the pancreas caused by
the lymphocyte infiltration. Although the seroconversion to islet
autoantibody positivity has been the first detectable signal for the
onset of autoimmunity and progression towards diabetes [2], the
initiators of autoimmune response, mechanisms regulating pro-
gress toward beta cell failure and factors determining time of
presentation of clinical diabetes are poorly understood.
We recently investigated changes in the serum metabolome
prospectively in a unique cohort of children at genetic risk for
T1D. Intriguingly, we detected multiple changes related to
dysregulation of lipid and amino acid metabolism preceding the
autoimmunity and overt T1D [3]. In order to better understand
the early diabetes pathogenesis, it would have been therefore of
great importance to study the molecular mechanisms behind the
early metabolic dysregulation as related to the autoimmune
response, an area so far neglected in T1D research.
Motivated by our clinical findings, here we study molecular paths
associated with the incidence of type 1 diabetes (T1D) and insulitis in
the Non-Obese Diabetic (NOD) mouse model using the available
gene expression data from young pre-diabetic mice [4]. The NOD
mouse isa strainwhoseimmune system sharesmanysimilarities with
human’s immune system as well as the autoimmune response [5]. It
is therefore widely used in studies aiming to elucidate T1D, although
it is also clear that this experimental model may only in part reflect
the the immune system and T1D pathogenesis in human [6]. We
introduce a method EMPath (Enriched Molecular Pathdetection) for
detection of molecular paths of physical interactions in an integrated
network of protein-protein interactions, signal transduction maps
and metabolic pathways by applying a modified version of the color
coding algorithm [7]. The color coding algorithm was applied
previously to detect signaling pathways derived from protein
interaction networks [8]. In our approach the phenotype context is
achieved by the introduction of path weights based on the network
structure combined with the mRNA expression data. Our aim is to
detect paths in an integrated network such that up- or down-
regulated protein nodes, as estimated by the gene expression data,
aresignificantlyover-represented onthe path incomparisonwith the
rest of the network (Figure 1).
Results and Discussion
Detection of molecular paths associated with insulitis
and type 1 diabetes incidence
We applied the EMPath method to an integrated network of
protein-protein interactions, signal transduction maps and meta-
bolic pathways where the nodes are proteins or metabolites and
the edges are interactions or reactions. In order to study the
network in the biological context, we used gene expression
information to weight the corresponding protein nodes.
Since our primary aim as related to T1D was to study tissue-
specific changes of molecular paths during the early disease
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pre-diabetic mice with selected controls. We searched the
T1DBase [9] which hosts T1D related genetic and expression
data and identified the study by Vukkadapu et al. [4] as the only
suitable for our analysis. In addition to that study, there were two
other studies available in T1DBase; Chaparro et al. [10] and
Stanford RoadMap of NOD Type 1 Diabetes (http://fathmanlab.
stanford.edu/roadmap_study_design.html). However, we found
that Vukkadapu et al is more suitable for our analysis than these
studies. Chaparro et al. contains data from 6-, 9- and 15 week old
mice, whereas Vukkadapu et al. investigated 3 week old mice. The
young mice are more informative for the goals of our study since
insulitis is known to occur until 3 or 4 week of age [5]. Standford
RoadMap has not yet been published in any journal as of August
2009. However, once available this data will include young mice
and will probably provide relevant data in the context of early
disease pathogenesis in NOD mice.
In the study by Vukkadapu et al. [4], the pancreatic tissue gene
expression data is available for four NOD mouse strains from 3
week old animals: BDC2.5/NOD, NOD, BDC2.5/NOD.scid,
and NOD.scid. The data analysis in the primary publication was
focusing primarily on known T1D-related genes associated with
the autoimmune response and inflammation [4]. The four
experimental models studied by Vukkadapu et al. have differences
in the incidence of insulitis and T1D. The BDC2.5/NOD and
NOD mice have accelerated and slow insulitis development,
respectively. Therefore, comparison of these mouse models may
provide information about the pathways associated with early
insulitis although as a limitation one should also keep in mind that
this not an ideal comparison since genetic factors associated with
e.g. age and growth are not controlled for. The BDC2.5/NOD.scid
model has extremely high diabetes incidence, which develops
already at 3–4 weeks of age, whereas the NOD.scid does not
develop diabetes. The pathways associated with differences
between these two mouse models may thus provide information
about mechanisms specific to late insulitis and T1D.
We performed path detection for the two comparisons: (1)
BDC2.5/NOD vs. NOD (early insulitis) and (2) BDC2.5/NOD.vs.
NOD.scid (late insulitis and early T1D). We detected multiple
optimal paths at p,0.025 threshold in both case-control
combinations (Figures S2–S5). Selected high scoring paths are
shown in Figure 2. Two serine/threonine-protein phosphatases,
2A (PP2A) and 5 (PP5) were members of the most upregulated
paths in early insulitis (Figure S2). PP2A and PP5 are known to
interact [11], and PP2A is associated with the autoimmune
response in systemic lupus erythematosus [12]. Interestingly, PP2A
is also a regulator of insulin secretion in pancreatic beta cells [13]
and its activation is required for repression of PPARa, a key
regulator of genes involved in beta cell fatty acid oxidation [14].
Several paths including lipid metabolism enzymes were found
downregulated in early insulitis (Figure S3, Table S1). Lipid
phosphate phosphohydrolase 3 (LPP3) hydrolizes specific phos-
pholipids in the lipid membrane, leading to production of e.g.
diacylglycerols and ceramides [15]. Two of the enzymes of
carnitine metabolism, carnitine O-palmitoyltransferase I (CPT1)
and 4-trimethyl aminobutyraldehyde dehydrogenase (TMA-
BADH), were also downregulated in the BDC2.5/NOD mice.
Interestingly, the dihydroxyacetone phosphate acyltransferase
(DHAPAT; Uniprot ID P98192), a key regulator of ether
phospholipid synthesis [16], was found in a downregulated path
in close proximity of CPT1 (Figure S3).
Two interacting members of the cytochrome P450 family,
CYP1B1 and CYP1A1, were found upregulated and present in
multiple paths associated with late insulitis and T1D (Figure S4),
while basigin (CD147 antigen, also named extracellular matrix
metalloproteinase inducer) was found in several downregulated
paths (Figure S5). CD147 is a receptor of cyclophilins and is an
important messenger of intercellular communication involved also
in recruitment of leukocytes from the periphery into tissues during
inflammatory responses [17].
As a potential limitation of our approach, in the path detection
method presented here we assign weights to nodes based on
mRNA expression data and not on protein concentration or direct
interaction data. The protein-level data would be ideal for our
approach, but such data is generally not available at the global
scale such as in transcriptomics studies. We thus use the protein
encoding mRNA expression as an approximation, although it is
well known that mRNA and corresponding protein level do not
always correlate [18]. Although approximate, we believe that use
of mRNA expression when protein-level data is unavailable or too
sparse is justified and can still provide useful hints about the
molecular paths associated with the investigated phenotypes.
Functional characterization of molecular paths
To better understand the paths detected by EMPath in the
context of known pathways, we assessed the functional enrichment
of detected paths similarly as previously described [8]. We cross-
classified the proteins from a molecular path according to whether
or not their encoding genes belong to gene sets obtained from the
Molecular Signature Database (MSigDB) [19] and tested if the
number of those genes associated with the path is larger than
expected by chance using the hypergeometric test. We corrected
the p-values for multiple comparisons using the False Discovery
Rate (FDR) q-values. By setting the statistical significance level at
FDR q,0.05, we identified multiple gene sets over-represented
among the detected molecular paths (Table S2). As a summary,
the top ten enriched pathways in each of the case-control settings
are shown in Table 1.
It is evident from Table 1 that early insulitis (i.e. BDC2.5/NOD
strain, as compared to NOD) is associated with altered cell
signaling since multiple (de)phosphorilation pathways are affected.
In contrast, the lipid metabolism is diminished. The paths
associated with late insulitis and T1D in BDC2.5/NOD.scid
strain are related to cell communication and related processes,
Figure 1. Enriched molecular path detection concept. Illustrative
example of path detection in a complex network of interacting entities.
An enriched path of 6 entities is highlighted.
doi:10.1371/journal.pone.0007323.g001
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Upregulated (C) and downregulated (D) paths related to late insulitis and T1D.
doi:10.1371/journal.pone.0007323.g002
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to cell cycle and DNA repair, is impaired.
Comparison of path detection with pathway analysis
We performed Gene Set Enrichment Analysis (GSEA) [19] for
both case-control comparisons. Table 2 contains the top scored
pathways for each strain at FDR q,0.05, while a full list of affected
pathways at recommended q,0.25 is shown in Tables S3–S6. In
agreement with earlier analyses [4], both EMPath (Table 1) and
GSEA analyses confirmed multiple inflammatory and T cell
activation pathways in pancreatic tissue in late insulitis and early
T1D. The cell proliferation, division, as well as nucleotide synthesis
pathways were found diminished, confirming increasing cell death
and DNA damage at this late stage of disease pathogenesis.
In accordance with path detection results, lipid metabolism
related pathways (fatty acid metabolism and bile acid synthesis) are
downregulated in insulitis, while the cell cycle related pathways are
downregulated in T1D (Table 2). The CPT1 and TMABADH
Table 1. Top enriched pathways in insulitis and type 1 diabetes as derived from detected paths.
Gene set Source n(P & G) n(G) Nominalp-value FDR q-value
Enriched in upregulated paths (BDC2.5/NOD vs. NOD)
PTDINSPATHWAY BioCarta 3 19 0.000004 0.000103
HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM KEGG 3 27 0.000012 0.000155
HSA00530_AMINOSUGARS_METABOLISM KEGG 2 16 0.000025 0.000280
GALACTOSE_METABOLISM GenMAPP 2 20 0.000596 0.003099
HSA00052_GALACTOSE_METABOLISM KEGG 2 24 0.000863 0.003738
GLUCONEOGENESIS GenMAPP 2 39 0.002286 0.006604
GLYCOLYSIS GenMAPP 2 39 0.002286 0.006604
HSA04630_JAK_STAT_SIGNALING_PATHWAY KEGG 4 100 0.000118 0.008023
HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY KEGG 3 62 0.000150 0.008426
GHPATHWAY BioCarta 2 24 0.000863 0.016104
Enriched in downregulated paths (BDC2.5/NOD vs. NOD)
GLYCEROLIPID_METABOLISM GenMAPP 3 24 ,10
26 0.000011
STATIN_PATHWAY_PHARMGKB GenMAPP 2 16 0.000152 0.000557
HSA00565_ETHER_LIPID_METABOLISM KEGG 2 21 0.000441 0.002093
HSA00071_FATTY_ACID_METABOLISM KEGG 2 29 0.000847 0.002311
HSA00120_BILE_ACID_BIOSYNTHESIS KEGG 2 20 0.000399 0.002311
HSA00220_UREA_CYCLE_AND_METABOLISM_OF_AMINO_GROUPS KEGG 2 21 0.000441 0.002311
HSA00310_LYSINE_DEGRADATION KEGG 2 29 0.000847 0.002311
HSA00340_HISTIDINE_METABOLISM KEGG 2 19 0.000359 0.002311
HSA00410_BETA_ALANINE_METABOLISM KEGG 2 17 0.000286 0.002311
HSA00620_PYRUVATE_METABOLISM KEGG 2 28 0.000789 0.002311
Enriched in upregulated paths (BDC2.5/NOD.scid vs. NOD.scid)
EGFPATHWAY BioCarta 4 25 ,10
26 0.000040
HSA04630_JAK_STAT_SIGNALING_PATHWAY KEGG 5 100 0.000002 0.000102
HSA05213_ENDOMETRIAL_CANCER KEGG 4 42 0.000004 0.000128
HSA05223_NON_SMALL_CELL_LUNG_CANCER KEGG 4 43 0.000004 0.000128
CTLA4PATHWAY BioCarta 3 15 0.000008 0.000131
ERK5PATHWAY BioCarta 3 16 0.000010 0.000131
HSA05214_GLIOMA KEGG 4 50 0.000007 0.000131
PTENPATHWAY BioCarta 3 16 0.000010 0.000131
NGFPATHWAY BioCarta 3 17 0.000012 0.000140
IGF1PATHWAY BioCarta 3 18 0.000014 0.000149
Enriched in downregulated paths (BDC2.5/NOD.scid vs. NOD.scid)
PYRIMIDINE_METABOLISM GenMAPP 3 43 0.000010 0.000061
HSA00230_PURINE_METABOLISM KEGG 3 90 0.000096 0.000334
NDKDYNAMINPATHWAY BioCarta 2 16 0.000898 0.006367
HSA05110_CHOLERA_INFECTION KEGG 1 31 0.039815 0.046451
Top ten enriched gene sets at FDR q,0.05 defined in the Molecular Signature Database [19], using the gene lists derived from the detected paths (Figures S2–S5). The
p-value is obtained from the hypergeometric test. Column legend: n(P&G), number of common genes in the detected path and the gene set; n(G), number of genes in
the gene set.
doi:10.1371/journal.pone.0007323.t001
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S1) were both among the leading edge genes in the fatty acid
metabolism gene set, while TMABADH was also the leading edge
in the bile acid synthesis module.
Meta analysis of findings using T1DBase
To investigate how genes detected by EmPath change in gene
expression analyses seen in several other studies, we used the Meta
Analysis tool of the T1DBase (http://www.t1dbase.org/page/Meta-
Home) [9]. As a result, we selected the genes found in the significant
molecular paths (Figure 2) and visualized their differential expression
across multiple studies available in T1Dbase (Figures S6–S9).
We can see some interesting observations regarding the genes
that were involved in our detected paths. DHAPAT (often
abbreviated as GNPAT), a gene that was found in paths
downregulated in early insulitis in paths detected by EmPath, was
also down-regulated in mice deficient for transcriptional regulators
FoxA2 and Sox4 [20,21]. PP2(also abbreviated as PPP2CA), a gene
that was upregulated in early insulitis and type 1 diabetes in paths
detected by EmPath, was also upregulated in FoxA2 deficient
mouse [20]. Another interesting observation is that the up-/down-
regulation of molecular paths in early insulitis in our study matches
particularly well with the data from the FoxA2 deficient mouse
(Figures S6–S7 and reference [20]). FoxA2 is a transcription factor
involved in the regulation of insulin sensitivity [22].
Ether lipids and oxidative stress in beta cells
As a most surprising finding from our study, multiple lipid
pathways were downregulated in early insulitis (BDC2.5/NOD vs.
NOD comparison), including the ether lipid metabolism (Table 1).
Ether phospholipid synthesis, including synthesis of plasmalogens,
starts in peroxisomes and involves esterification of dihydroxyace-
tone phosphate (DHAP) with a long-chain acyl-CoA ester [16,23]
(Figure 3). This first reaction is catalyzed by dihydroxyacetone
phosphate acyltransferase (DHAPAT, EC 2.3.1.42). This reaction
appears to be affected in early insulitis, since the path involving
DHAPAT is diminished (Tables 1 and S1, Figure S3). The
plasmalogens are the most abundant ether phospholipids and may
protect cellular functions from oxidative damage [24,25]. The ether
lipids were also found consistently diminished in serum of children
who later progressed to type 1 diabetes [3]. Diminished protection
against the reactive oxygen species is relevant for T1D since
pancreatic beta cells are particularly susceptible to oxidative
damage [26,27]. Further supporting the role of lipids in early
Table 2. Top scored pathways in GSEA.
Gene set Size Enrichment Score Nominal p-value FDR q-value Source
Downregulated paths (BDC2.5/NOD vs. NOD)
HSA03010_RIBOSOME 44 20.61 0.000466 0.0027 KEGG
WNTPATHWAY 22 20.63 0.002375 0.0252 BioCarta
HSA00071_FATTY_ACID_METABOLISM 29 20.58 0.001845 0.0291 KEGG
CALCINEURINPATHWAY 17 20.64 0.007370 0.0392 BioCarta
PROTEASOMEPATHWAY 21 20.61 0.004710 0.0418 BioCarta
BILE_ACID_BIOSYNTHESIS 15 20.65 0.007466 0.0425 GenMAPP
Upregulated paths (BDC2.5/NOD.scid vs. NOD.scid)
HSA04610_COMPLEMENT_AND_COAGULATION_CASCADES 52 0.62 ,10–5 0.0022 KEGG
HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION 33 0.66 ,10–5 0.0038 KEGG
HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 74 0.54 ,10–5 0.0107 KEGG
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 169 0.47 ,10–5 0.0183 KEGG
NKCELLSPATHWAY 15 0.71 0.002838 0.0310 BioCarta
HSA04940_TYPE_I_DIABETES_MELLITUS 20 0.66 0.002753 0.0353 KEGG
Downregulated paths (BDC2.5/NOD.scid vs. NOD.scid)
CELL_CYCLE_KEGG 58 20.57 ,10–5 0.0031 GenMAPP
CELL_CYCLE 53 20.56 ,10–5 0.0073 GO
UBIQUITIN_MEDIATED_PROTEOLYSIS 20 20.67 0.000937 0.0096 GenMAPP
G1_TO_S_CELL_CYCLE_REACTOME 54 20.53 ,10–5 0.0112 GenMAPP
HSA00190_OXIDATIVE_PHOSPHORYLATION 86 20.49 ,10–5 0.0113 KEGG
P53PATHWAY 16 20.70 0.001388 0.0144 BioCarta
PROTEASOMEPATHWAY 21 20.64 ,10–5 0.0174 BioCarta
HSA04120_UBIQUITIN_MEDIATED_PROTEOLYSIS 25 20.62 0.000473 0.0177 KEGG
HSA04110_CELL_CYCLE 82 20.47 0.000553 0.0211 KEGG
CARM_ERPATHWAY 19 20.63 0.004144 0.0279 BioCarta
MRNA_PROCESSING_REACTOME 83 20.46 ,10–5 0.0312 GenMAPP
HSA00510_N_GLYCAN_BIOSYNTHESIS 24 20.59 0.003738 0.0356 KEGG
G2PATHWAY 18 20.62 0.004585 0.0475 BioCarta
This table contains top scored gene sets in GSEA for each strain (FDR q,0.05). The gene sets studies are the same as in the analysis for Table 1. None of the pathways
were significantly upregulated in the BDC2.5/NOD vs. NOD comparison using the FDR q,0.05 threshold.
doi:10.1371/journal.pone.0007323.t002
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transport to mitochondria (CPT1 and TMABADH) were found in
downregulated paths as well.
Previous genetic studies have shown that defective plasmalogen
synthesis associates with impaired membrane trafficking [28]
although the implications for type 1 diabetes remain to be
established [29]. Plasmalogen synthesis-related genes such as
DHAPAT clearly need to be evaluated as potential type 1 diabetes
susceptibility genes. The complete depletion of ether lipids via a
genetic DHAPAT knock-out model leads to a severe phenotype,
including arrest of spermatogenesis, development of cataract and
defects in central nervous system myelination [30]. In order to
study the physiological consequences of altered ether lipid levels as
observed in pre-diabetes, one would therefore need to establish
experimental models with partial depletion of ether lipids.
Conclusions
We demonstrated that graph-theoretic approaches such as
EMPath are a useful tool for detecting pathways of physical
interactions associated with specific disease phenotypes. Our
findings from the study of paths associated with early insulitis and
T1D are consistent with recent findings from a large scale clinical
metabolomics study, suggesting an important role of lipid
metabolism in the early stages of T1D pathogenesis. We provide
evidence that such dysregulation of lipid metabolism and related
oxidative stress may be tracked to beta cells and may thus explain
the beta cell loss due to increased oxidative stress. The genes
identified as important in early insulitis such as DHAPAT or PP2A
clearly need to be investigated further in the context of early T1D
pathogenesis as well as for their therapeutic potential.
Materials and Methods
Construction of integrated network
We constructed an integrated interaction network by combining
protein-protein interactions, signal transduction maps and meta-
bolic pathways in mouse as described previously [31,32]. The
integrated network nodes stand for proteins or metabolites, and
edges stand for interactions between nodes. We retrieved protein-
protein interactions from BIND [33], MINT [34] and DIP [35],
signal transduction interactions from TransPath [36] and biochem-
ical reactions from KEGG [37]. We excluded highly connected
cofactors from the network since they do not participate in the
actual metabolic conversions as substrates or products. Therefore,
their inclusion would connect many metabolically distant enzymes.
The excluded cofactors are listed in the Supplementary Table S7.
Gene expression data
We obtained normalized gene expression data from the T1D
dataset [4] from NCBI Gene Expression Omnibus (GEO)
database [38] series accession number: GSE1623. We used the
samples GSM27446 (BDC2.5/NOD1), GSM27451 (BDC2.5/
NOD.scid_1), GSM27453 (NOD.scid1) and GSM27456 (NOD1)
in all the analyses presented in this paper. In the source mouse
model experiments [4], RNA hybridization was done on
Affymetrix gene chip platform MGU74AV2.
Edge and node weights
The color coding algorithm used in [8] was not suitable for
detecting paths in phenotypic context, since they did not have any
phenotypic weights. Their weights were solely based on reliabilities
of interactions. We modified the color coding algorithm so that it
works in phenotypic manner by assigning weights to nodes. We
did the weight assignment for each mouse model comparison
separately. In order to find the up-regulated paths, we assigned
case-control ratios. And to find down-regulated paths, we assigned
control-case ratios as weights to nodes. We can thus use the color
coding algorithm to find maximum paths in both cases.
We assigned equal weights of 1.0 to all edges from MINT, DIP,
KEGG and TransPath, while the edges from BIND were set to
0.33, reflecting large database size of BIND and its reliability of
interactions [39].
Path scoring
The path score is computed as follows. In order to give high penalty
for a cascade of unreliable edges, we first multiply all edge weights. In
order to reward inclusion of high weight nodes, we sum up all node
weights. In the end, we multiply the edge product and the node sum.
More precisely, the path scoring scheme is presented in Figure S10 and
Formulas (1)–(3) below. We thus move forward on a path by selecting a
node and edge so that the total weight is maximized. However, we are
not allowed to move forward to a node if its color is inside the sliding
window (read more in the next paragraph).
w edgeProd ðÞ ~wE 12 ðÞ   wE 23 ðÞ   wE 23 ðÞ   :::  wEn {1 ðÞ n ðÞ ð 1Þ
w nodeSum ðÞ ~wN 1 ðÞ zwN 2 ðÞ zwN 3 ðÞ z:::zwN n ðÞ ð 2Þ
wt o t ðÞ ~we d g e Prod ðÞ   w nodeSum ðÞ ð 3Þ
We used a color coding algorithm for detecting optimal paths
[7]. The basic idea of this algorithm is to assign colors (i.e., integers)
Figure 3. Schematic representation of the steps involved in the
biosynthesis of ether phospholipids, including plasmalogens. The
lipids found consistently downregulated in serum of children who later
developed type 1 diabetes [3] are shown in green box. DHAPAT enzyme is
found in the downregulated paths in early insulitis in the present study
(green arrow). The first three reactions in the pathway take place in
peroxisomes, while the others are catalyzed by microsomal enzyme systems.
Other routes for the formation of ether phospholipids may exist [16].
doi:10.1371/journal.pone.0007323.g003
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twice. The restriction on colors guarantees that the detected path is a
simple path. When the network is very large, the applicability of this
algorithm is challenged by the large computer memory requirements.
To address this limitation, we extended the algorithm by using a sliding
windowsothatthedistinct color requirement applies only to nodes that
are inside the window (Figure S1). That is, unlike the original algorithm
which allows no two nodes in a path to have the same color, our
algorithm allows no two nodes within the length of the sliding window
to have the same color. We first tried to detect a path by using a
window length that is equal to the length of detected path. If we did not
find a path, we decreased the window length by 1 until we found a path
or the window length became 1. This modification improves the
performance because it avoids storing of the whole path in computer
memory. The algorithm is thus faster and it is capable of detecting
longer paths. It is thus more applicable to integrated networks that are
usually very large. However, in principle the original version could be
used in integrated networks, but it is more probable that there appear
memory problems.
Statistical significance of a path
In order to test for the null hypothesis that the detected path is
obtained by chance, we calculated the p-values. In order to
calculate one p-value, we shuffled node and edge weights 10,000
times. For the purpose of computational efficiency, we first tested
how promising the p-value looks after each shuffle based on the
pre-specified cutoff criterion (p-value ,0.025), then jumped into
the next path if the criterion was not met. The full algorithm for
the p-value calculation is described in the Supplementary Text S1.
Network harvesting
A network is considered harvested if all optimal paths in the
network are detected. However, there is not any rigorous way to
define when the network is harvested, so we took a heuristic
approach by assuming that the network is harvested if we come up
with 50 consecutive iterations in which the detected path is
previously detected. However, since the p-value calculation for an
optimal path is computationally expensive, we also limited
ourselves to finding at most two optimal paths of the same length
in each network (i.e., in each mouse model comparison). It is easy
to increase this number of paths if required. The algorithm is
described in the Supplementary Text S2.
Characterization of paths
We used a hypergeometric test to identify gene sets from the
MSigDB [19] that are over-represented in the molecular paths
detected by the EMPath method. First, as a quality control criterion,
we restricted the searches to gene sets compiled from pathway
databases KEGG, BioCarta, GenMAPP, and GO. Next, we defined
the Gene Symbol Universe by taking the union of all genes in the selected
gene sets. Next, we translated the Swissprot accession numbers of
protein nodes of the molecular paths to the Gene Symbols of their
encoding genes. These translations are done using Affymetrix
annotations of the mouse gene chip platform MGU74Av2, the
platform used for NOD mice gene expression experiments. Finally, by
using the function phyper of the R stats package [40] we tested for
enrichment of each gene set in each molecular path. In order to
account for multiple comparisons, the Benjamini and Hochberg’s
method for controlling the false discovery rate was applied [41].
Gene Set Enrichment Analysis
We performed Gene Set Enrichment Analysis (GSEA) of the
T1D gene expression data [4] using Java desktop version of the
software (February 2006 release). We performed GSEA separately
for the two selected phenotype comparisons. Since there was only
one sample per phenotype, giving one gene expression value per
gene per phenotype, we used the ratio of classes statistic of the GSEA
for ranking genes. We accessed the gene sets defined in the
MSigDB [19] and annotations for the Affymetrix gene chip
platform MGU74AV2 via ftp pages of GSEA from within the
software interface. The GSEA statistics were computed using
5,000 gene set permutations.
T1DBase Meta Analysis
First, we selected proteins from the paths detected by EmPath
(Figures S2–S5). They were annotated by Uniprot identifiers. We
then used EMBL database to find EMBL identifiers for
corresponding genes. The NCBI Entrez gene database (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=gene) was then searched
to find Entrez gene identifiers for those genes. We used these
identifiers on the web user interface of the T1DBase Meta analysis
tool (http://www.t1dbase.org/page/MetaHome). We performed
the expression comparison by using all studies that were available
in the Beta Cell Biology Consortium.
Supporting Information
Text S1 The algorithm for calculating significance of optimal
paths detected by EMPath method (p-value calculation).
Found at: doi:10.1371/journal.pone.0007323.s001 (0.04 MB
DOC)
Text S2 Network harvesting algorithm.
Found at: doi:10.1371/journal.pone.0007323.s002 (0.03 MB
DOC)
Table S1 Genes found in downregulated paths in insulitis.
Found at: doi:10.1371/journal.pone.0007323.s003 (0.04 MB
DOC)
Table S2 Significantly enriched pathways in insulitis and type 1
diabetes as derived from detected paths.
Found at: doi:10.1371/journal.pone.0007323.s004 (1.06 MB
DOC)
Table S3 Enriched upregulated pathways in insulitis.
Found at: doi:10.1371/journal.pone.0007323.s005 (0.03 MB
DOC)
Table S4 Enriched downregulated pathways in insulitis.
Found at: doi:10.1371/journal.pone.0007323.s006 (0.09 MB
DOC)
Table S5 Enriched upregulated pathways in type 1 diabetes.
Found at: doi:10.1371/journal.pone.0007323.s007 (0.05 MB
DOC)
Table S6 Enriched downregulated pathways in type 1 diabetes.
Found at: doi:10.1371/journal.pone.0007323.s008 (0.08 MB
DOC)
Table S7 Excluded cofactors.
Found at: doi:10.1371/journal.pone.0007323.s009 (0.08 MB
DOC)
Figure S1 Use of a sliding window to optimize the path
detection. The distinct color requirement applies only inside the
window. We therefore do not need store the whole path in
memory, which makes the detection process faster. In this figure
we have an example in which our window size is 2. Our path
detection is at a stage in which we have traversed from A- to B to
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7323C. And we have {2,3} in denied colors. We can thus continue to
either D or E.
Found at: doi:10.1371/journal.pone.0007323.s010 (1.00 MB
DOC)
Figure S2 Upregulated paths in BDC2.5/NOD vs. NOD
comparison. The nodes are colored using the same color code as
in Figure 2. Edge annotations related to the source database: K,
KEGG; M, MINT.
Found at: doi:10.1371/journal.pone.0007323.s011 (1.30 MB
DOC)
Figure S3 Downregulated paths in BDC2.5/NOD vs. NOD
comparison. The nodes are colored using the same color code as in
Figure 2. Edge annotations related to the source database: K,
KEGG; M, MINT.
Found at: doi:10.1371/journal.pone.0007323.s012 (1.30 MB
DOC)
Figure S4 Upregulated paths in BDC2.5/NOD.scid vs. NOD.s-
cid comparison. The nodes are colored using the same color code
as in Figure 2. Edge annotations related to the source database: K,
KEGG; M, MINT.
Found at: doi:10.1371/journal.pone.0007323.s013 (1.30 MB EPS)
Figure S5 Downregulated paths in BDC2.5/NOD.scid vs.
NOD.scid comparison. The nodes are colored using the same
color code as in Figure 2. Edge annotations related to the source
database: K, KEGG; M, MINT.
Found at: doi:10.1371/journal.pone.0007323.s014 (1.26 MB EPS)
Figure S6 Meta-analysis for upregulated genes in BDC2.5/
NOD vs. NOD comparison. Genes are presented as rows and
study group comparisons as columns.
Found at: doi:10.1371/journal.pone.0007323.s015 (1.87 MB EPS)
Figure S7 Meta-analysis for downregulated genes in BDC2.5/
NOD vs. NOD comparison. Genes are presented as rows and
study group comparisons as columns.
Found at: doi:10.1371/journal.pone.0007323.s016 (1.86 MB EPS)
Figure S8 Meta-analysis for upregulated genes in BDC2.5/
NOD.scid vs. NOD.scid comparison. Genes are presented as rows
and study group comparisons as columns.
Found at: doi:10.1371/journal.pone.0007323.s017 (2.25 MB EPS)
Figure S9 Meta-analysis for downregulated genes in BDC2.5/
NOD.scid vs. NOD.scid comparison. Genes are presented as rows
and study comparisons as columns.
Found at: doi:10.1371/journal.pone.0007323.s018 (1.67 MB EPS)
Figure S10 Path scoring method. In order to calculate the score
for the path, the edge weights are multiplied. All node weights are
then summed up. In the end, the edge product and the node sum
are multiplied. The total path score is thus (w(E12)* w(E23)*..*
w((n-1)N)))*(W(N1)+ W(N2)+..+ W(Nn)).
Found at: doi:10.1371/journal.pone.0007323.s019 (1.00 MB EPS)
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